Source: Covexit

video

In this video, Dr Peter McCullough, from the Baylor University Medical Center in Texas, explains how important early outpatient treatment is and presents guidelines for such treatment.

He relies on an article on outpatient treatment published by himself and several co-authors, including Yale professor, medical doctor and epidemiologist Harvey Risch.

Dr McCullough collaborated with medical doctors in the US and Italy to come up with practical guidelines for practitioners for the early outpatient treatment of COVID-19.

He explains that patients who present to hospital generally do so after two weeks of illness, and are already severely ill.

They are put into isolation, do receive supportive care, and there has been some advancement with therapies. Hopefully they will survive, he says, adding, that sadly, many won’t.

“Outpatient treatment is the only hope for reducing the risk of hospitalization and death” affirms Dr McCullough

Dr McCullough and his collaborators developed an emergency program for the outpatient treatment of COVID-19. 

The findings were published in the American Journal of Medicine on August 6. 

Dr McCullough present them as the first published peer reviewed treatment guidelines for practitioners who are caring for ambulatory COVID-19 patients.







Related:

Belgium Study: Low-dose Hydroxychloroquine Therapy and Mortality (Lowered) in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants

C19study.com update: Now 88 international studies (51 peer reviewed) show positive hydroxychloroquine treatment outcomes

Italy Study 3,451 patients: Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study

China Study of 2882 patients: Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »

The Chloroquine Wars Part XIV – How to Rig Research: Surgisphere Part I

It was in these very moments in late May when public health officials lost all credibility—a credibility that cannot be restored without major changes taking place. Despite most evidence pointing to a likelihood of HCQ efficacy, they made their call on the back of data supposedly tucked away in a database that nobody had verified, declared it definitive, then swiftly pushed for policy changes around the world.

Read More »

Another New York State Supreme Court Justice Ivermectin Order Helping 81-Year-Old Farmer

Ivermectin, a medicine for parasites, has been around for four decades. While not authorized for use against COVID-19, dozens of studies show materially positive results. At well-established human dosage levels, the drug is safe: hundreds of millions of people are treated with it every year mostly in the tropics for various parasite-borne diseases, such as River Blindness in Nigeria.

Read More »

The Chloroquine Wars Part XIII -A Clockwork Orange Man

Immediately following HCQ’s Trump moment, the media went on an all-out blitz to associate the topic of HCQ with a sense of fear. Fear of Trump, fear of death, fear of incompetence, fear of opposing scientific authorities, fear of using medicine needed by somebody else, and fear of the unknown. And the campaign of fear didn’t stop there.

Read More »